| Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer JHA Clubb, TV Kudling, C Heiniö, S Basnet, S Pakola, VC Carrascón, ... Frontiers in Immunology 13, 2022 | 31 | 2022 |
| Systemic delivery of oncolytic adenovirus to tumors using tumor-infiltrating lymphocytes as carriers J Santos, C Heiniö, D Quixabeira, S Zafar, J Clubb, S Pakola, ... Cells 10 (5), 978, 2021 | 31 | 2021 |
| Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression TV Kudling, JHA Clubb, DCA Quixabeira, JM Santos, R Havunen, ... Oncoimmunology 11 (1), 2096572, 2022 | 27 | 2022 |
| Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer TV Kudling, JHA Clubb, S Pakola, DCA Quixabeira, IAK Lähdeniemi, ... OncoImmunology 12 (1), 2241710, 2023 | 11 | 2023 |
| Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial SA Pakola, KJ Peltola, JHA Clubb, E Jirovec, L Haybout, TV Kudling, ... Clinical Cancer Research, OF1-OF11, 2024 | 10 | 2024 |
| Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors S Basnet, JM Santos, DCA Quixabeira, JHA Clubb, ... Molecular Therapy-Oncolytics 28, 59-73, 2023 | 10 | 2023 |
| Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting JHA Clubb, TV Kudling, M Girych, L Haybout, S Pakola, F Hamdan, ... Frontiers in Immunology 14, 212, 0 | 6 | |
| Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine DCA Quixabeira, E Jirovec, S Pakola, R Havunen, S Basnet, JM Santos, ... Cancer Gene Therapy 30 (11), 1543-1553, 2023 | 5 | 2023 |
| 48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a … TJ Monberg, S Pakola, B Dreno, V Cervera-Carrascon, E Ellebæk, ... Immuno-Oncology and Technology 20, 2023 | 3 | 2023 |
| An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast … S Pakola, DCA Quixabeira, TV Kudling, JHA Clubb, ... Frontiers in Immunology 14, 2023 | 3 | 2023 |
| Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer DCA Quixabeira, S Pakola, E Jirovec, R Havunen, S Basnet, JM Santos, ... Cancer Gene Therapy 30 (12), 1679-1690, 2023 | 2 | 2023 |
| 749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors–Interim results J Santos, I Svane, K Peltola, T Alanko, R Korpisaari, S Juteau, M Jaakkola, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | 1 | 2023 |
| 1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor … J Santos, K Peltola, T Alanko, SA Pakola, J Clubb, E Jirovec, L Haybout, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 2), 2023 | 1 | 2023 |
| 805 Oncolytic adenovirus encoding human interleukin-7 in combination with ICIs as a treatment strategy against renal cell carcinoma (RCC) V Arias, T Kudling, J Clubb, L Haybout, E Jirovec, SA Pakola, S Basnet, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial SA Pakola, V Cervera-Carrascon, K Peltola, T Alanko, R Korpisaari, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 806 Oncolytic adenovirus coding for human Mucin1 T cell engager with interleukin-2 potentiates anti-tumor T cell responses against tumors S Basnet, M Van der Heijden, E Jirovec, J Clubb, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in … TV Kudling, J Clubb, SA Pakola, DA Quixabeira, I Lähdeniemi, C Heiniö, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 745 Immune cell profiling of advanced-stage solid tumors patients treated with an oncolytic adenovirus encoding for TNF-a and IL-2 (TILT-123) DCA Quixabeira, SA Pakola, J Clubb, L Haybout, E Jirovec, T Kudling, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours–from preclinical testing to phase I clinical trials J Clubb, V Cervera-Carrascon, K Peltola, T Alanko, R Korpisaari, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 51P Immunological analysis of blood from patients with solid tumors treated with TILT-123: An oncolytic adenovirus encoding for tumor necrosis factor alpha (TNFa) and … S Pakola, JM Santos, V Cervera-Carrascon, C Kistler, S Sorsa, ... Immuno-Oncology and Technology 16, 2022 | | 2022 |
